Further investigation into EMP1 may elucidate the mechanisms underlying its upregulation in MASLD-IRI and clarify its biological function, thereby supporting its potential as a diagnostic and therapeutic target. Here, EMP1 is linked to metabolic dysfunction-associated steatotic liver disease.